Alvotech (ALVOW)Luxembourg, Luxembourg | NasdaqGM
0.45 USD
|
Hot Take ↕ | Oct. 10, 2026, 1:53 a.m. EDT
The security is trapped in a severe structural decline with no path to recovery. Fundamentally, the business is deteriorating rapidly, evidenced by a massive 38.9% contraction in revenue and negative operating cash flows that indicate the company is burning through capital without generating returns. The balance sheet is critically impaired, carrying debt significantly higher than its cash reserves, resulting in negative book value and negative profit margins. Technically, the stock is at its 52-week low, having failed to generate any upward momentum despite a low beta, suggesting a lack of institutional support. With no dividend history to provide income and a complete absence of price history to suggest a turnaround, the investment case is non-existent. |
| Attribute | Value |
|---|---|
| Revenue per Share | 1.675 |
| Beta | 0.21 |
| Profit Margins | -36.31% |
| Website | https://www.alvotech.com |
| Attribute | Value |
|---|---|
| Address1 | 9, Rue de Bitbourg |
| Ask | 1.3 |
| Ask Size | 2 |
| Beta | 0.205 |
| Bid | 1.24 |
| Bid Size | 1 |
| Book Value | -0.537 |
| City | Luxembourg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Luxembourg |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.4496 |
| Current Ratio | 1.646 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.45 |
| Day Low | 0.4496 |
| Ebitda | 75,733,000 |
| Ebitda Margins | 0.15312 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.45 |
| Fifty Two Week High Change | -0.00039997697 |
| Fifty Two Week High Change Percent | -0.00088883773 |
| Fifty Two Week Low | 0.4496 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.4496 - 0.45 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 140,789,299 |
| Free Cashflow | -123,130,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,279 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 0.4496 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.60662 |
| Gross Profits | 300,038,016 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,022-06-16 |
| Language | en-US |
| Long Business Summary | Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. |
| Long Name | Alvotech |
| Market | us_market |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_693209405 |
| Net Income To Common | -179,590,000 |
| Open | 1.52 |
| Operating Cashflow | -198,702,000 |
| Operating Margins | -0.11052 |
| Previous Close | 0.4496 |
| Price Hint | 4 |
| Price To Book | -0.837244 |
| Profit Margins | -0.36310002 |
| Quick Ratio | 0.793 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.45 |
| Regular Market Day Low | 0.4496 |
| Regular Market Day Range | 0.4496 - 0.45 |
| Regular Market Open | 1.52 |
| Regular Market Previous Close | 0.4496 |
| Regular Market Price | 0.4496 |
| Regular Market Time | 1,791,297,888 |
| Regular Market Volume | 100 |
| Return On Assets | 0.02187 |
| Revenue Growth | -0.389 |
| Revenue Per Share | 1.675 |
| Sand P52 Week Change | 0.17502642 |
| Sector | |
| Sector Key | |
| Short Name | Alvotech Warrant |
| Source Interval | 15 |
| Symbol | ALVOW |
| Total Cash | 142,750,000 |
| Total Cash Per Share | 0.4 |
| Total Debt | 1,451,784,960 |
| Total Revenue | 494,608,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 100 |
| Website | https://www.alvotech.com |
| Zip | 1,273 |